Business By Sharon Begley Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own
First Opinion By Jonathan Kimball Trade agreement drug monopoly is obsolete given faster, better drug discovery
First Opinion By Carlos Sattler and Sheila Frame Biosimilar approval and adoption in the U.S. needs to be expedited
First Opinion By Michelle Hoffmann Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?
First Opinion By John E. Osborn Biologics lose protection as U.S.-Canada-Mexico trade agreement moves forward
Politics By Erin Mershon Drug makers jostle over potential Medicare changes in congressional spending deal
In the Lab By Eric Boodman Freeze-dried drug factories could make a slew of medicines — just add water
Pharmalot By Ed Silverman Unintended twist in Obamacare may cost some Medicare patients more for biosimilars